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DiStasi MR, Unthank JL, Miller SJ. Nox2 and p47phox modulate
compensatory growth of primary collateral arteries. Am J Physiol
Heart Circ Physiol 306: H1435–H1443, 2014. First published March
14, 2014; doi:10.1152/ajpheart.00828.2013.—The role of NADPH
oxidase (Nox) in both the promotion and impairment of compensatory
collateral growth remains controversial because the specific Nox and
reactive oxygen species involved are unclear. The aim of this study
was to identify the primary Nox and reactive oxygen species associ-
ated with early stage compensatory collateral growth in young,
healthy animals. Ligation of the feed arteries that form primary
collateral pathways in rat mesentery and mouse hindlimb was used to
assess the role of Nox during collateral growth. Changes in mesenteric
collateral artery Nox mRNA expression determined by real-time PCR
at 1, 3, and 7 days relative to same-animal control arteries suggested
a role for Nox subunits Nox2 and p47phox. Administration of apocynin
or Nox2ds-tat suppressed collateral growth in both rat and mouse
models, suggesting the Nox2/p47phox interaction was involved. Func-
tional significance of p47phox expression was assessed by evaluation
of collateral growth in rats administered p47phox small interfering
RNA and in p47phox/ mice. Diameter measurements of collateral
mesenteric and gracilis arteries at 7 and 14 days, respectively, indi-
cated no significant collateral growth compared with control rats or
C57BL/6 mice. Chronic polyethylene glycol-conjugated catalase ad-
ministration significantly suppressed collateral development in rats
and mice, implying a requirement for H2O2. Taken together, these
results suggest that Nox2, modulated at least in part by p47phox,
mediates early stage compensatory collateral development via a pro-
cess dependent upon peroxide generation. These results have impor-
tant implications for the use of antioxidants and the development of
therapies for peripheral arterial disease.
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FLOW-MEDIATED OUTWARD REMODELING constitutes a major, nat-
ural compensation to arterial occlusions such as those occur-
ring in peripheral vascular disease. This compensation relies on
the development of preexisting bypass arteries into collateral
pathways by a process of luminal enlargement [see Ziegler et
al. (78) for review]. The outward remodeling that occurs as part
of the collateral growth process is dependent on chronically
increased flow and shear stress, and the process halts when
shear stress has been restored to initial levels (23, 30, 65).
While collateral growth may largely compensate for peripheral
arterial occlusions due to injury or disease in some cases (14,
27), risk factors associated with vascular dysfunction and
oxidant stress, such as aging, diabetes, and hypertension, may
impair this process in humans and animals (1, 2, 26, 33, 48, 62,
64). Recent studies have implicated oxidative stress, possibly
due to NADPH oxidase (Nox)-derived reactive oxygen species
(ROS), as a primary mechanism responsible for impaired
vascular compensation to arterial occlusion (4, 45, 46), and
these same studies demonstrated that administration of an
antioxidant reversed the impairment. The results of such stud-
ies suggest that the use of antioxidant therapy to reduce excess
ROS may be effective as primary or adjuvant means to pro-
mote vascular compensation to arterial occlusion. However,
other studies performed with conduit or resistance vessels in
the absence of ROS-associated risk factors have demonstrated
that ROS are required for flow-mediated remodeling (3, 7, 8).
Thus additional studies are needed to better understand the
origin and roles of ROS and Nox in both the promotion and
impairment of flow-mediated remodeling and collateral devel-
opment.
The primary source of ROS in the vasculature is thought to
be the family of Nox enzymes that includes Nox1, -2, -4, and
-5 and their associated regulatory subunits such as p22phox,
p47phox, p40phox, and p67phox [see Lassegue et al. (39) for
review]. Nox1, -2, and -4 are present in rodent vasculature,
whereas Nox5 is present only in humans. The contribution of
Nox activation to oxidant stress in the context of pathological
remodeling has been extensively studied (39), but less is
known about the role and regulation of Nox during physiolog-
ical remodeling, especially in the smaller arteries that form
collateral pathways. Early evidence indicated a flow-mediated
mechanism for free radical release from large artery endothe-
lium (40), and more recent work has shown that Nox may be
activated by increased shear stress (19). While evidence exists
from several studies for Nox-mediated redox control of altered
peripheral tissue perfusion in response to arterial ligation (20,
59, 69), these studies do not directly evaluate compensatory
enlargement of the small feed arteries that form the primary
collaterals. The limited data available on the function of Nox in
flow-mediated compensatory remodeling indicate either that
Nox2 plays a role in mediating the luminal expansion (3) or
suggest a role for p47phox but not Nox2 (7, 17). However, the
influence on the results of these studies due to differences in
flow/shear level, artery type, or compensation in whole animal
models with genetic deletion are not known.
Although superoxide is the primary, immediate product of most
Nox activity, subsequent dismutation generates hydrogen perox-
ide, which is longer-lived and thus may diffuse further into the
vasculature. Excess peroxide is known to be a damaging ROS that
participates in the development of vascular pathology (32, 73) and
to inhibit physiological processes (20, 25), but physiological
concentrations have been shown to facilitate vascular processes
such as capillary growth or angiogenesis (55, 70) and arterial
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dilatation (31). Although increased flow has been shown to
stimulate peroxide production in coronary arterioles of young rats
(31), its role in collateral growth is unclear.
The objective of the current study was to determine the
identity of the primary Nox associated with early stage collat-
eral growth in young, healthy animals. A second objective was
to determine if peroxide had a role in compensatory collateral
development. To address these issues, we used both rat mes-
enteric and mouse hindlimb femoral artery ligation models that
allowed diameter measurements in conjunction with molecular
and pharmacological approaches, including Nox subunit abla-
tion, small interfering RNA (siRNA), and pharmacological
inhibition. Taken together, the results indicate important roles
for Nox2 and hydrogen peroxide in compensatory collateral
development in young, healthy animals.
METHODS
Animals and groups. All procedures performed in this study were
approved by the Indiana University School of Medicine Institutional
Animal Care and Use Committee. Young male Wistar-Kyoto (WKY)
rats were obtained from Charles River (Wilmington, MA), acclimated
for a minimum of 3 days before use and studied at 2 to 3 mo of age.
Male C57BL/6 and p47phox/ mice were obtained from Jackson
Laboratories (Bar Harbor, ME) and studied at 4.5–6 mo of age.
Apocynin (acetovanillone) was obtained from Fisher Scientific (Pitts-
burg, PA), Nox2ds-tat (gp91ds-tat) and scramble peptides were cus-
tom synthesized by EZbiolabs (Westfield, IN) according to Rey et al.
(53), and polyethylene glycol-conjugated catalase (PEG-CAT) was
from Sigma-Aldrich (St. Louis, MO). Apocynin (3.0 mM; 60
mg·kg1·day1) was administered in drinking water 3 days before
model creation and continued until final experimentation when vessel
diameters were obtained. The Nox2ds-tat peptide (rats, 1.0
mg·kg1·day1; and mice, 10 mg·kg1·day1) and PEG-CAT
(10,000 U·kg1·day1) were delivered via Alzet osmotic pumps
(Durect, Cupertino, CA: rat, 2ML1; and mouse, 1002). The pumps
were aseptically implanted in a subcutaneous pocket in the nape of the
neck at the time of arterial ligation. Concentrations/doses of agents
were derived from earlier studies that demonstrated effectiveness in
reducing oxidative stress (41, 49, 53, 57), normalizing arterial ROS
and nitric oxide (NO) concentrations (76, 77), affecting arterial
remodeling (3, 45, 46), or suppressing mesenteric artery mRNA
expression (72). The p47phox siRNA (ON-Target Plus SmartPool
duplex; Thermo Scientific/Dharmacon, Pittsburg, PA) was adminis-
tered via tail vein using the hydrodynamic method as previously
described (66). Briefly, 50 g (230 g/kg) of p47phox siRNA or
SmartPool universal siRNA control (Dharmacon) was reconstituted
with RNase-free water and diluted to a final volume of 6.0 ml with
TransIT in vivo transfection agent (Mirus Bio, Madison, WI). The
siRNA was injected 1 day before collateral model creation, with a
second injection of25 g at day 4, and final diameter measurements
were made on day 7 as described below.
Model of rat mesenteric collateral growth and its assessment.
Experiments used a well-characterized model of mesenteric artery
collateral growth as previously described (46, 65). This model uses
sequential ligation of mesenteric arteries to create a flow-dependent
collateral pathway and allows comparison of high-flow collateral
arteries to in-animal control arteries that have not experienced in-
creased flow. Briefly, a laparotomy was performed on an anesthetized
WKY rat, and the terminal ileum was exteriorized into a heated tissue
support chamber. The bowel and mesentery were immersed in phos-
phate-buffered saline or covered with plastic wrap at all times to
prevent tissue desiccation. Several sequential ileal arteries were li-
gated such that a region of bowel containing 45 microvascular
perfusion units was dependent upon collateral arteries for perfusion
[see Miller et al. (46) for model illustration]. Digital images of the two
primary collateral and two same-animal control arteries were acquired
under conditions of maximal dilation (0.1 mM adenosine and 0.01
mM sodium nitroprusside) with a dissecting microscope (Leica MZ
9.5; Leica Microsystems, Buffalo Grove, IL) and camera (Spot Insight
4 Firewire; SPOT Imaging Solutions, Sterling Heights, MI). The
bowel was returned to the abdominal cavity and the incision closed.
After 7 days, the laparotomy and acquisition of digital images was
repeated [see Miller et al. (46) for example images]. From these
images, inner arterial diameter was determined by measuring the red
cell column (mean of 3 measurements/artery) with image analysis
software (ImageJ, National Institutes of Health) and the percent
change in diameter was calculated.
Model of mouse hindlimb collateral growth and its assessment. A
model of focal arterial occlusion was created in C57BL/6 and
p47phox/ mice as previously described (17) by ligating the distal
superficial femoral artery, as this is the most common site of occlusion
in patients with peripheral arterial disease (44a, 71). Ligation at this
site increases flow through the gracilis arteries, which form the
primary collateral pathways in this model (9, 17). To perform the
ligation, an 7-mm incision was made in the skin above the origin of
the saphenous artery under 2.5% inhaled isoflurane anesthesia via
aseptic technique. The femoral vein and nerve were gently teased
away from the artery, and a ligation was made using 6-0 sterile silk
suture placed proximal to the trifurcation of the femoral, but distal to
the origin of the superficial epigastric artery [see diagram in supple-
mental Fig. S1 in DiStasi et al. (17)]. Following ligation, 5-0 sterile
absorbable suture was used to close the skin. Throughout the proce-
dure, great care was taken to keep vessels and tissues moist and to
minimize trauma to adjacent tissue in an attempt to minimize local
inflammation. At 14 days postligation, the animal was anesthetized
and then perfused at physiological pressure with 10 ml of the same
dilator cocktail as used for the rat model above, followed by 10 ml of
4% Zn-formalin via anterograde cannulation of the infrarenal abdom-
inal aorta with polyethylene-50 tubing. To allow visualization and
subsequent diameter measurements of the gracilis collaterals,0.1 ml
of Microfil vascular casting compound (Flow Tech, Carver, MA) was
advanced through the aortic cannula into both hindlimbs until retro-
grade filling of the saphenous artery distal to the ligation was apparent
(17). The carcasses were enveloped in plastic wrap and stored at 4°C
overnight to allow for complete curing of the casting agent. The
midzone (42) of the gracilis collaterals as well as the same-animal
contralateral controls were then carefully dissected, in situ digital
images of the control and collateral vessels were obtained at matching
locations in both limbs [see (17) for example images], and vessel
diameters were determined with image analysis software (ImageJ).
Quantitative RT-PCR. Relative differences in mesenteric artery
Nox subunit mRNA expression were determined using reverse tran-
scription real-time quantitative PCR as previously described (45).
Briefly, RNA was isolated from control and collateral mesenteric
arteries perfused with cold phosphate-buffered saline followed by
RNAlater (Ambion, Austin, TX). Following perfusion, the jejunum,
ileum, and cecum with intact mesenteric vasculature were excised and
placed on a prechilled silicone elastomer-coated petri dish for dissec-
tion. Control and collateral arteries extending from the superior
mesenteric artery to the marginal artery near the bowel wall were
isolated from the mesenteric neurovascular bundle. Before excision,
each isolated artery was carefully cleaned under a dissecting micro-
scope to remove adventitial tissue to limit cellular sources of Nox
primarily to the media and intima. If not processed immediately,
arteries were preserved in RNAlater at 20°C before RNA isolation.
Tissues were disrupted using a bead homogenizer (FastPrep System;
QBIOgene, Carlsbad, CA) followed by total RNA purification using
an RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, CA), which
included on-column DNase digestion. RNA sample concentration was
determined using A260/A280 (NanoDrop ND1000 Spectrophotome-
ter; NanoDrop Products, Wilmington, DE), and RNA integrity was
verified by analysis with either an Agilent 2100 Bioanalyzer (RNA
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6000 Nano Chip Kit; Agilent, Santa Clara, CA) or Experion auto-
mated electrophoresis station (RNA HighSens chips; Bio-Rad, Her-
cules, CA). Aliquots of purified total RNA (0.3 g) were enzymati-
cally treated to remove potential contaminating genomic DNA (DNA-
free Ambion) and then reverse transcribed using Ready-To-Go You-
Prime First-Strand Beads (GE Healthcare/Amersham Biosciences,
Piscataway, NJ) with random decamer priming. For PCR, aliquots of
cDNA (5.0 l, 1:50 dilution) were combined with primers and probes
for Nox1, Nox2, Nox4 (PrimeTime qPCR Assays; Integrated DNA
Technologies, Coralville, IA), and p47phox or hexokinase endogenous
control (TaqMan Gene Expression Assays; Applied Biosystems, Fos-
ter City, CA) in the presence of a PCR master mix (FastStart
Universal Probe Master Mix; Roche Applied Science, Indianapolis,
IN). Reactions were run in triplicate on an Applied Biosystems 7500
Real-Time PCR System using relative quantification ( threshold
cycle) with dual-labeled (FAM/MGB) probes as the product detection
method. Standard two-step 7500 PCR cycling conditions (40 cycles)
were used. Differences in PCR product yields between groups were
determined by comparing the fold differences between target mRNAs
after normalization to hexokinase. We have found hexokinase to be
invariant between control and collateral arteries, and its expression
level closely matches that of the Nox subunits studied (S. J. Miller;
unpublished observation).
Statistics. Statistical analyses were done by one- or two-way
repeated-measures ANOVA (SigmaPlot 12.0). When significance
between groups was detected, multiple pairwise comparisons were
performed with the Holm-Sidak method. Data are presented as group
means  SE. The criterion for significance was P  0.05.
RESULTS
Assessment of temporal Nox expression. To assess the po-
tential involvement of Nox subunits during collateral remod-
eling, collateral artery mRNA expression of Nox1, -2, -4, and
p47phox relative to control arteries was determined at 1, 3, and
7 days postligation. These time points were chosen to focus on
the intervals before and during the most rapid phase of collat-
eral growth in the rat mesenteric model (63). As shown in Fig. 1,
various temporal expression patterns were observed for the
different Nox components. Collateral mRNA expression was
significantly increased for Nox2 at all three time points, with
the greatest changes at 3 and 7 days. In contrast, p47phox
expression was significantly increased at both 1 and 3 days, but
by 7 days was normalized to control values. Nox4 expression
was significantly elevated only at 3 days, but to a lesser extent
than either Nox2 or p47phox. Although detectable, Nox1 ex-
pression was too low to quantify using the same conditions as
for the other Nox subunits. Taken together, the results indi-
cated a potential role for selected Nox components in early
stage collateral development.
Nox2/p47phox interaction and collateral growth. The in-
creased expression of Nox2 and p47phox in the initial period of
collateral growth (1–3 days) and subsequent decreased p47phox
expression at 7 days suggested these interacting catalytic and
regulatory subunits may have a role in mediating the early
stage collateral growth. To test this possibility, we first verified
redox regulation of collateral growth by administering a gen-
eral antioxidant and determining the effect on collateral artery
diameter change. As shown in Fig. 2A, apocynin completelyFig. 1. Temporal expression of NADPH oxidase (Nox) mRNA in rat mesen-
teric collateral artery. Changes in collateral artery Nox mRNA subunit expres-
sion at 1, 3, and 7 days were determined compared with same animal control
arteries and expressed as a collateral-to-control ratio (*, , #: P  0.05 vs.
control, 1 day, 3 day, respectively; n 	 4–6).
Fig. 2. Antioxidant treatment or Nox2 inhibition suppress rat mesenteric
collateral growth. A: mesenteric artery control and collateral artery diameters
(7-day model) were determined in rats receiving plain drinking water (un-
treated, n 	 6) or water supplemented with 3 mM apocynin (n 	 4). (*, ;
P  0.001 vs. untreated control and untreated collateral, respectively). B:
control and collateral artery diameters were determined in rats receiving
scramble ds-tat (n 	 4) or Nox2ds-tat (1 mg·kg1·day1; n 	 3) delivered via
osmotic minipump (*, ; P  0.001 vs. scramble ds-tat control and scramble
ds-tat collateral, respectively). Collateral growth is expressed as percent
change because the mesenteric ligation model allows for artery diameter
measurements of the same vessel at time 0 and at 7 days postligation.
H1437NOX2 AND COLLATERAL GROWTH
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00828.2013 • www.ajpheart.org
 by 10.220.33.3 on Decem
ber 22, 2016
http://ajpheart.physiology.org/
D
ow
nloaded from
 
inhibited collateral growth compared with untreated controls.
Because apocynin may act as a Nox2 inhibitor in vivo (29), in
addition to other antioxidant properties (28), we next assessed
effects of the selective Nox2 inhibitor Nox2ds-tat (gp91ds-tat),
which inhibits interaction of Nox2 and p47phox (11, 53), on
collateral growth. As depicted in Fig. 2B, administration of
Nox2ds-tat, but not the scrambled peptide, prevented any
significant collateral growth in young WKY rats.
We next confirmed the role of the Nox2/p47phox interaction
in collateral development using an alternative vascular bed.
Apocynin or Nox2ds-tat was administered to separate groups
of C57BL/6 mice that had undergone a femoral artery ligation
to induce gracilis artery collateral growth. As shown in Fig. 3,
both agents resulted in a significantly reduced capacity to
develop gracilis artery collaterals, consistent with the results
from the rat mesenteric model.
Regulation of collateral growth by p47phox expression. The
p47phox subunit is a key regulator of Nox1 and -2 activity (39),
and one study has shown that p47phox regulates flow-mediated
conduit artery remodeling (7). Based on this study, along with
our data showing temporal variations in Nox mRNA expres-
sion and the ability of Nox2ds-tat to inhibit collateral growth,
we hypothesized that changes in p47phox expression levels
could regulate early stage collateral growth. To address this
hypothesis, we used both a molecular and genetic approach.
First, we used a p47phox siRNA delivered systemically to WKY
rats to suppress p47phox expression in conjunction with the
mesenteric collateral model. The results in Fig. 4A show that
administration of p47phox siRNA completely suppressed col-
lateral growth in the young WKY rats compared with the
nonsense (negative) siRNA control. To verify this finding both
with genetic ablation and in an alternate collateral model,
femoral artery ligation was performed in p47phox/ mice and
hindlimb gracilis artery collateral growth was assessed at 14
days. Similar to the results with the rat mesenteric model,
hindlimb collateral growth was significantly attenuated in the
p47phox/ compared with the wild-type controls (Fig. 4B).
Role of peroxide in compensatory collateral growth. To
assess a potential requisite role of hydrogen peroxide in me-
diating collateral growth, PEG-CAT was administered contin-
uously via osmotic pump during the 7-day WKY rat mesenteric
model. As shown in Fig. 5, PEG-CAT prevented any signifi-
cant collateral growth from occurring compared with the ve-
hicle control, indicating that peroxide is necessary for compen-
satory collateral growth. When PEG-CAT was administered to
mice, significant collateral enlargement was observed (59.3 
1.1 vs. 82.5  1.9 m, control vs. collateral, respectively, P 
0.001, n 	 4). However, this 20-m increase in collateral
diameter was significantly less (P  0.02) than the 55-m
increase observed in the untreated mice (Fig. 3A), and the
suppression in collateral enlargement was similar to results
obtained with apocynin and Nox2ds-tat (Fig. 3, A and B).
DISCUSSION
Significant aspects of the current study findings may be
summarized in four main points: 1) the temporal changes in
expression of Nox subunits during early stages of collateral
growth, 2) the ability of apocynin and Nox2ds-tat to inhibit
collateral growth in both the rat and mouse models of collateral
development, 3) decreased or absent p47phox expression and
the inhibition of collateral growth, and 4) inhibition of collat-
eral growth by PEG-CAT. The significance of these points is
considered in detail below, following a brief discussion of the
rodent models’ relevance to the study.
Model considerations. The rat mesenteric and mouse
hindlimb models of collateral growth both use acute ligation of
select arteries to allow investigation of responses of primary
collaterals, which are the major determinants of resistance
following arterial occlusion in humans (10, 43, 61) and animals
(37, 68, 74). The rat mesenteric model is readily accessible and
Fig. 3. Antioxidant treatment or Nox2 inhibition suppresses mouse hindlimb
collateral growth. A: gracilis artery diameters were determined in unligated
(control) and ligated (collateral) limbs 14 days following femoral artery
ligation in mice receiving plain drinking water (untreated, n 	 8) or water
supplemented with apocynin (n	 6). (*,; P 0.05 vs. control and untreated
collateral, respectively). B: control and collateral artery diameters were deter-
mined in rats receiving scramble ds-tat (n 	 6) or Nox2ds-tat (10
mg·kg1·day1; n 	 5) delivered via osmotic minipump (*, ; P  0.05 vs.
control and scramble ds-tat collateral, respectively, determined by one-way
ANOVA). Collateral growth is expressed as control and collateral artery
diameters rather than percent diameter change because, unlike the rat mesen-
tery, diameter measurements in the mouse hindlimb are only possible at death.
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allows for repeated diameter measurements on the same artery.
It also has been well characterized in terms of hemodynamic
properties including shear stress (22, 63, 65, 67) and allows for
molecular analyses of mRNA and/or protein expression (e.g.,
collateral Nox subunit mRNA expression, Fig. 1). The hemo-
dynamics of collateral formation in the mouse hindlimb graci-
lis artery model are largely unknown, but this model is more
relevant to the focal occlusion which occurs in the human leg
and has the advantage of molecular knockouts to assess func-
tion of select proteins. These two different collateral models
were used in this study to allow for a combination of pharma-
cological, molecular, and genetic approaches to investigate the
role of specific Nox in redox-mediated physiological collateral
growth and to ensure the applicability of the results to more
than one type of vascular bed.
Temporal expression of Nox during collateral growth.
Changes in Nox expression were assessed by measuring rela-
tive mRNA expression changes for Nox1, -2, -4, and p47phox
subunits at 1, 3, and 7 days, following the creation of the
mesenteric collateral model. These time points were chosen
because they represent stages 1) before remodeling has begun
but transcriptional changes have occurred (day 1), 2) at which
both protein synthesis and the earliest measureable increase in
diameter have occurred (day 3), and 3) when flow-mediated
remodeling is in a rapid period of development and significant
artery diameter change can be easily detected (day 7) (63, 66,
67). Because of the relatively low expression level of Nox1, we
assumed its contribution to redox regulation of collateral
growth was negligible in this model. However, the possibility
of posttranscriptional regulation of Nox1 or related subunit
expression and/or activity cannot be ruled out. Nox2 and
p47phox, but not Nox4, subunit expression was consistently
increased at the earliest stages of collateral growth (days 1 and
3), and p47phox expression was normalized to control values at
day 7 (Fig. 1). Taken together, these results suggested that
Nox2 was potentially involved in early stages of collateral
development by regulation via changes in p47phox expression/
activity. These results are partially consistent with the findings
of Duerrschmidt et al. (19) that showed acute temporal changes
in predominantly Nox2-related ROS in response to elevated
shear. Belin de Chantemele et al. (3) noted that Nox2, but not
p47phox, expression was increased at 3 wk in a mesenteric
collateral model, which is consistent with the drop in p47phox
expression we observed at 7 days. Because the mRNA expres-
sion data implicated the Nox2/p47phox interaction in redox
regulation of the early stages of collateral development, we
investigated the relationship between Nox2 and collateral
growth using functional approaches.
Nox2 and p47phox as regulators of collateral growth. Be-
cause both apocynin and Nox2ds-tat prevent interaction of
Nox2 and the p47phox subunit (11, 29, 53), the observed
inhibition of collateral growth by these Nox inhibitors in both
rat mesenteric (Fig. 2) and mouse hindlimb (Fig. 3) models of
Fig. 4. p47phox inhibition suppresses collateral growth. A: mesenteric artery
control and collateral artery diameters (7-day model) were determined in rats
receiving small interfering RNA (siRNA) to p47phox (n 	 4) or to a nonsense
(negative control) siRNA (n 	 3). *, ; P  0.001 vs. control and nonsense
siRNA collateral, respectively. B: hindlimb collateral growth in p47phox/
(p47/) mice. Gracilis artery collateral diameters were measured at 14 days
following single ligation of the right femoral artery and compared with same
animal control limbs in C57BL/6 (C57; same as untreated in Fig. 3; n	 8) and
in p47/ (n 	 11). *, ; P  0.05 vs. control, C57BL/6 collateral,
respectively.
Fig. 5. Catalase inhibited rat mesenteric collateral growth. Polyethylene glycol-
conjugated catalase (PEG-CAT) and vehicle (saline) administration via os-
motic pump was started at the time of model creation and continued for 7 days.
Collateral diameters in vehicle-treated rats (n 	 3) significantly increased
compared with in-animal control arteries, whereas no collateral growth oc-
curred in the rats receiving PEG-CAT (n	 4). *,; P 0.001 vs. control and
vehicle collateral, respectively.
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collateral formation strongly implicates the Nox2/p47phox in-
teraction as a key component in redox-mediated collateral
growth. Apocynin may have antioxidant actions independent
from its action as an in vivo Nox inhibitor (28); nevertheless,
its ability to suppress luminal expansion is consistent with the
action of Nox2ds-tat, suggesting its primary action in these
collateral models is via Nox inhibition. This result is consistent
with that obtained by Henrion’s group (3) who showed that
chronic treatment with Tempol or apocynin blocked collateral
growth in the rat mesenteric model. The Nox2 B-loop peptide,
on which the Nox2ds-tat peptide is based, recently has been
shown to be selective for the Nox2/p47phox interaction (11),
and administration of Nox2ds-tat completely suppressed col-
lateral growth in the young WKY rats (Fig. 2B). Nox2ds-tat
also significantly reduced development of the gracilis collateral
in the mouse hindlimb (Fig. 3B), suggesting Nox2 is an
important component of redox signaling in small arteries with
characteristics different from the mesenteric circulation. It is
known that p47phox also can be a regulatory subunit for Nox1,
but because the expression level of Nox1 was so low in the
mesenteric arteries, we interpret this observation to mean that
it is not a major source of vascular ROS involved in redox
signaling, at least in this model. We also have observed that
Nox1 mRNA expression in mouse femoral/iliac vessels was
similar to rat mesenteric; insufficient to accurately quantify
compared with the expression of other Nox subunits analyzed
under the same conditions (S. J. Miller, unpublished observa-
tion).
The current study determined the role of Nox2 in resistance
vessels forming primary collateral pathways using clinically
relevant well-defined models of subcritical ischemia. The ma-
jor stimulus for the outward remodeling of these collateral
vessels is the wall shear stress associated with increases in
volume flow through the collateral vessels (21, 63). We are
aware of only two other studies that have examined the
relationship between Nox2 and flow-dependent remodeling
using Nox2/ mice. Castier et al. (7) used a high-flow carotid
model and found that Nox2/ mice had normal outward
remodeling compared with wild-type mice. However, the re-
sults of this study demonstrated a requirement for p47phox
flow-mediated remodeling, consistent with our observations.
DiStasi et al. (17) used a mouse hindlimb model with femoral
artery excision and determined gracilis collateral artery growth
to be unimpaired in Nox2/ mice, which is inconsistent with
our current results.
The explanation for the divergent role of Nox2 in these two
studies compared with the current report is unknown but could
relate to the magnitude of the stimulus and vascular heteroge-
neity in Nox expression. In the Castier et al. study (7), shear
stress was increased 
5 compared with control versus 2
in the rat mesenteric model (67). Likewise, the excision of the
entire femoral artery as used by DiStasi et al. would be
expected to elevate shear stress in collaterals to a greater
degree than in the current paper with single ligation of the same
artery. The level of shear stress could directly influence Nox
activation in the endothelium and indirectly in the medial layer
where circumferential wall stress could be influenced by flow-
mediated dilation. In addition, the localization of the various
Nox within the vascular wall is complex and may vary between
vascular location and species (5). It has been reported that
Nox2 typically present in resistance vessels may be replaced by
Nox1 in conduit vessels (38), and this could also explain the
observed difference between the carotid and mesenteric vessels
exposed to elevated flow. In the carotid, p47phox could function
as a regulatory subunit for Nox1, and the possibility of in-
creased compensatory expression/activity of Nox1 in Nox2/
mice exposed to higher levels of shear stress cannot be ruled
out. Recent work also suggests that p47phox may have effects
independent of Nox activity regulation (50). However, this
possibility would seem unlikely in our collateral models be-
cause the Nox2 inhibitor data in both rat and mouse (Figs. 2
and 3) provide compelling evidence for p47phox regulation of
the Nox2 complex as a mechanism for generating the ROS
involved in normal collateral development. While a role for
Nox4 in collateral growth cannot be entirely ruled out, espe-
cially in the mouse, the rat PCR data indicate minimal expres-
sion changes in early stages of mesenteric artery remodeling.
Studies have indicated a role for Nox4 in compensatory vas-
cular function, but primarily in the context of angiogenesis (13,
55, 75) or dilatation (51) and not remodeling of resistance
vessels. It also has been suggested that the function of Nox4 is
significant only during disease or stress conditions and not in
normal physiological function (60). Clearly, further work is
needed to delineate the role of the various Nox in compensa-
tory and pathological adaptations in vascular tissues.
Potential role of hydrogen peroxide in collateral growth.
The ability of PEG-CAT to suppress collateral growth (Fig. 5)
suggests hydrogen peroxide is an important form of ROS
regulating compensatory collateral growth. Increased flow has
been shown to stimulate acute peroxide production in rat
coronary resistance arterioles (31), and it has been demon-
strated that peroxide can participate in physiological processes
such as angiogenesis and the regulation of vascular dilation.
Schroder et al. (55) found that PEG-CAT inhibited angiogen-
esis in the hindlimbs of control mice, and Kang et al. (31)
showed that flow-induced dilation of 4-mo-old F344 rat coro-
nary arterioles was reduced by treatment with CAT. The
current results extend these previous findings on peroxide
function to the context of physiologically relevant chronically
elevated flow and collateral growth.
A potential mechanism for flow-mediated peroxide-depen-
dent collateral growth may be provided by the findings of
Kumar et al. (34), who showed that a shear-mediated decrease
in CAT (due to a decrease in PKC- activity) occurs in
pulmonary aortic endothelial cells, which increases hydrogen
peroxide signaling and results in elevated endothelial NO
synthase activity and NO production. Several studies (6, 18,
58, 70, 76) have established that physiological concentrations
of peroxide regulate endothelial NO synthase activity and the
resultant production of NO, which is an important mediator of
collateral development (12, 36). Peroxide has also been re-
cently shown to stabilize the mRNA for soluble guanylate
cyclase, which increases its expression and facilitates the
action of NO (44). Another potential contributing mechanism
for the action of peroxide on collateral growth is posttranscrip-
tional regulation of placenta growth factor, a known regulator
of arteriogenesis (56).
Although not a focus of this study, a related consideration
for the role of peroxide in collateral growth is its primary
source. While Nox4 may be a primary source for peroxide
under certain conditions (16), our previous work showed that
Nox2 is a source of peroxide production, at least in the context
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of risk factor-impaired vascular function (76, 77). In addition,
cross talk between Nox2-derived ROS and mitochondria has
been demonstrated to result in mitochondrial overproduction of
ROS, including peroxide [see Dikalov (15) for a review]. Thus,
while additional work will be needed to understand the specific
pathways involved in Nox-mediated peroxide production and
function, our results raise the possibility that Nox2-derived
peroxide is a primary ROS involved in redox signaling asso-
ciated with compensatory collateral growth.
Summary. The results from the current study are consistent
with the hypothesis that Nox2 is the primary Nox associated
with the normal redox signaling necessary for flow-mediated
compensatory remodeling in resistance vessels of young,
healthy animals. Taken together with our previous work show-
ing the ability of antioxidants to reverse the age- and hyper-
tension-related impairment in collateral growth (45, 46), the
current results also are consistent with the concept of an
“optimal redox window,” where relative amounts of ROS and
other redox-regulated molecules such as NO must be in bal-
ance for prevention of vascular dysfunction/disease and to
allow vascular processes to proceed normally (24, 35, 52, 54).
In addition, our results suggest that hydrogen peroxide is the
key ROS mediating compensatory collateral growth. Due to
the potential use of Nox pharmacological inhibitors and other
antioxidants to treat pathological vascular conditions related to
oxidant stress, it will be important to understand the role of
specific Nox subunits and ROS in both the promotion and
impairment of collateral growth. In particular, use of general or
Nox-specific antioxidants as preventive therapy for young
and/or healthy humans may be inappropriate due to potential
suppression of normal vascular functions such as flow-medi-
ated dilation or compensatory remodeling. More work will be
needed to fully delineate the specific Nox-related redox sig-
naling pathways involved in both physiological and risk-factor
impaired compensatory collateral growth.
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